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Abstract
Molecular testing for mutations in the EGFR gene is commonplace for patients with non-small cell lung cancer
(NSCLC). These patients are often very sick and management decisions need to be made urgently. In many cases,
the results of molecular testing are needed the same day, in order to start targeted therapy and allow maximum
benefit for patients. The Idylla™ EGFR Mutation Test offers rapid results within three hours of requesting. This
study aimed to assess the concordance of Idylla™ EGFR Mutation Test results with current standard tests. Forty
formalin-fixed, paraffin-embedded NSCLC tumour cases (20 EGFR mutant and EGFR 20 wild type) were analysed
by the Idylla™ EGFR Mutation Test (CE-IVD) and compared with PCR and NGS methodologies. The overall
concordance between Idylla™ and standard testing was 92.5% (95% CI 80.14% to 97.42%) and the specificity of
Idylla™ was 100% (95% CI 83.89% to 100%). The sensitivity was affected by loss of tumour content in tissue
blocks in a small number of NGS cases; however, comparing Idylla™ with PCR alone, there was 100% concor-
dance (95% CI 89.85% to 100%). The Idylla™ EGFR Mutation Test shows comparative accuracy to routine PCR
testing for the most common EGFR mutations in NSCLC. The Idylla™ also offers significantly reduced turn-around
times compared with existing modalities and therefore the platform would be a useful addition to many molecular
diagnostics units.
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Introduction
Lung cancer is the third most common cancer in the UK with
around 46,000 cases diagnosed each year. The prognosis for
these patients is extremely poor with the overall 10-year sur-
vival at only 5% [1]. Non-small cell lung carcinoma (NSCLC)
accounts for 85% of these tumours [2] and while surgery and
chemoradiotherapy remain the conventional management for
most patients, newer targeted therapies have shown great
promise in specific subgroups. Around 16% of NSCLC pa-
tients have somatic mutations in the epidermal growth factor
receptor (EGFR) gene and these patients show a greater re-
sponse to EGFR-tyrosine kinase inhibitors (EGFR-TKi), such
as gefitinib, than they do to traditional chemotherapies.
Conversely, patients without such mutations respond better
to conventional drugs. In the UK, guidance from the
National Institute for Health and Care Excellence (NICE) rec-
ommends that EGFR testing is therefore carried out for all
adults with previously untreated, locally advanced or metasta-
tic NSCLC in order to inform clinical management in these
Key messages
• EGFR testing in lung cancer is now routine and guideline driven, but has
long turn-around times
• The Idylla EGFRMutation Test offers rapid, same-day testing
• This study demonstrates high concordance of Idylla with routine PCR
methodologies for molecular testing in lung cancer
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patients. A number of next-generation sequencing (NGS) and
polymerase chain reaction (PCR) tests for detecting (EGFR)
mutations are approved by NICE; however, these all generally
involve long preparation, require significant staff training, re-
sult in a turn-around time of several days (usually due to the
need to batch cases), require large tissue volumes and invari-
ably incur high cost [3–5].
The Idylla™ EGFR Mutation Test is a novel test to detect
EGFR mutations in lung cancer, covering all the clinically rel-
evant mutations in exons 18 to 21 (Table 1). The test is a single-
use disposable cartridge that can carry out automated PCR on a
single section of formalin-fixed paraffin-embedded (FFPE) tis-
sue containing as little as 10% tumour cells. This requires min-
imal skill and equipment and can achieve an on-demand result
within three hours from the time of the pathologist requesting
the test [9]. There have been a number of publications to date
showing the high diagnostic accuracy of the Idylla™ System for
mutations in BRAF and KRAS in various tissues, but fewer
publications exist for EGFR testing with the platform [10–16].
Recent evidence demonstrates high concordance of the proto-
type (non-CE marked, research use only) Idylla™ EGFR
Mutation Test with conventional methods [17–20]. This study
evaluated the new CE-IVD approved Idylla™ EGFRMutation
Test with the main aim to verify the previous validations of the
RUO test in a small cohort of patients who have undergone
routine PCR testing. We also included a small set of NGS-
tested samples to get an indication of how the Idylla would fair
against such sequencing assays that are becoming popular and
have very low limits of detection.
Materials and methods
Ethical approval was granted by the National Research and
Ethics Service (Ethical Application Reference 04/Q1604/21;
Expiry Date 04/06/2021). Anonymised cases of FFPE lung
NSCLC were drawn from the histopathology diagnostic ar-
chive at Birmingham Heartlands Hospital and the Cambridge
Human Research Tissue Bank, Addenbrooke’s Hospital,
Cambridge. For the validation, 40 cases were selected: 20
EGFR mutant and 20 EGFR wild type, as determined retro-
spectively by the local standard care test. In Birmingham, PCR
was the reference standard and this was either the cobas EGFR
Mutation Test (Roche Molecular Systems Inc.) or the
therascreen EGFR RGQ PCR Kit (Qiagen), depending upon
when the test was carried out. For cases from Cambridge, the
reference test was the Ion AmpliSeq™ Cancer Hotspot Panel
v2 (Life Technologies). The original H&E sections were exam-
ined by a histopathologist and the same tissue area for Idylla™
testing was selected as was originally tested with the reference
standard. Idylla™ testing was carried out retrospectively at the
John Radcliffe Hospital in Oxford. The general principles and
methods for Idylla™ testing have been described previously
[10]. Briefly, formalin-fixed paraffin-embedded (FFPE) tumour
tissue was either enriched with macro-dissection (resection
specimens) from single 5-μm unstained sections on glass slides
or unenriched single 5-μm unstained FFPE rolls (small biop-
sies) were directly submitted for each test. All Idylla™ testing
samples met the minimum requirement of tissue with > 10%
tumour nuclei content (no minimum tissue dimensions are
specified by the manufacturer but a minimum of 2 mm2 was
used in all cases). FFPE tissue for testing was placed between
wetted blotting paper inside an Idylla™ cartridge, which was
loaded onto the Idylla™ system for processing. The Idylla™
console software auto-analysed the fluorescent amplification
signal to report the presence or absence of a mutation. The
presence of a mutation was considered a positive Idylla™ test
and wild type was considered negative [10].
The analysis focused on concordance between testing mo-
dalities, but also estimated the sensitivity and specificity of the
system. Statistical calculations were carried out using standard
formulae with Microsoft Excel.
Table 1 Details of the available EGFR assay on the Idylla system
compared with the commonly used NGS (Ion Torrent) platform. Turn-
around times and detection limits (analytical sensitivity) are given as
quoted by the manufacturers. The Ion PGM (NGS) panel is that described
on the Thermo Fisher website. The manufacturer explains that the theo-
retical turn-around time (sample to result) for this panel can be as low as a
single day or 24 h—however in practice with sample batching and routine
laboratory working hours, the results often take several days [6]
Gene Target Idylla [7] Ion PGM (NGS) [8]
EGFR Idylla EGFRMutation Test [9]
Coverage: Exon 18 point mutations (G719A/C/S), exon 19
deletion (Del9, Del12, Del15, Del18, Del21, Del24),
exon 20 point mutations (T790 M, S768I) and insertions
(insG, insASV9, insASV11, insSVD, insH), exon 21
point mutations (L858R, L861Q)
Detection limit: ‘≤ 5% for most prevalent EGFR mutations’
Turn-around time: 2 h (approx.)
AmpliSeq Cancer Hotspot Panel v2 [6]
Coverage†:
Detection limit: 98% detection rate for 5% variant frequency at
positions with average sequencing coverage from × 1000 to × 4000
Turn-around time: Single day
*Terminating codon notation
†Coverage given is for the codon changes that are likely to be relevant in CRC
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Results
The raw data from the comparison of Idylla™ and reference
testing can be found in Table 2. Twelve cases were biopsies,
28 were resections. There were two cases of squamous cell
carcinoma and 38 cases of adenocarcinoma. There was agree-
ment between Idylla™ and standard testing in 37 of the 40
cases giving an overall concordance of 92.5% (95% CI
80.14% to 97.42%) (Table 3). The estimated technical sensi-
tivity given this was 85% (95% CI 63.96% to 94.76%), while
Table 2 The raw data of the
comparison between Idylla and
reference tests including cobas,
therascreen and Ampliseq for
EGFR testing. Idylla mutations
given as reported by the system.
The test cannot distinguish
between some point mutations
(e.g. G719A vs. G719C vs.




Specimen Reference test Idylla Results
1 Lung: adenocarcinoma Exon 21 L858R (therascreen) Exon 21 L858R
2 Lung: adenocarcinoma Exon 20 ins (cobas) Exon 20 ins
3 Lung: adenocarcinoma Exon 18 G719A/C/S (therascreen) Exon 18 G719A/C/S
4 Lung: adenocarcinoma WT (cobas) WT
5* Lymph node: SCC WT (cobas) WT
6* Subcarinal tissue: adenocarcinoma Exon 19 del (therascreen) Exon 19 del
7 Lung: adenocarcinoma Exon 21 L858R (therascreen) Exon 21 L858R
8* Paratracheal tissue: adenocarcinoma Exon 19 del (therascreen) Exon 19 del
9* Lymph node: adenocarcinoma Exon 21 L858R (therascreen) Exon 21 L858R
10* Pleura: adenocarcinoma Exon 19 del (therascreen) Exon 19 del
11 Lung: adenocarcinoma WT (therascreen) WT
12 Lung: adenocarcinoma WT (cobas) WT
13 Lung: adenocarcinoma WT (therascreen) WT
14 Lung: adenocarcinoma WT (therascreen) WT
15 Lung: adenocarcinoma WT (therascreen) WT
16 Lung: adenocarcinoma Exon 19 del (therascreen) Exon 19 del
17 Lung: adenocarcinoma WT (therascreen) WT
18 Lung: adenocarcinoma Exon 21 L858R (therascreen) Exon 21 L858R
19 Lung: adenocarcinoma Exon 19 del (cobas) Exon 19 del
20 Lung: adenocarcinoma Exon 18 G719A/C/S (therascreen) Exon 18 G719A/C/S
21 Lung: adenocarcinoma Exon 21 L858R (therascreen) Exon 21 L858R
22 Lung: adenocarcinoma WT (cobas) WT
23 Lung: adenocarcinoma WT (therascreen) WT
24 Lung: adenocarcinoma WT (therascreen) WT
25* Lymph node: SCC WT (therascreen) WT
26 Lung: adenocarcinoma WT (cobas) WT
27 Lung: adenocarcinoma Exon 19 del (therascreen) Exon 19 del
28 Lung: adenocarcinoma WT (cobas) WT
29 Lung: adenocarcinoma Exon 21 L858R (therascreen) Exon 21 L858R
30 Lung: adenocarcinoma WT (cobas) WT
31 Lung: adenocarcinoma WT (cobas) WT
32 Lung: adenocarcinoma WT (cobas) WT
33 Lung: adenocarcinoma WT (therascreen) WT
34 Lung: adenocarcinoma Exon 19 del (therascreen) Exon 19 del
35* Lung: adenocarcinoma Exon 20 T790M (AmpliSeq)
(Incidental exon 18 E709_TdelinsD)
WT
36* Lung: adenocarcinoma Exon 19 del (AmpliSeq) Exon 19 del
37* Lung: adenocarcinoma WT (AmpliSeq) WT
38* Lung: adenocarcinoma Exon 21 L861Q (AmpliSeq) WT
39* Lung: adenocarcinoma Exon 20 S768I (AmpliSeq) WT
40* Lung: adenocarcinoma WT (AmpliSeq) WT
WT, wild type, del, deletion; in, insertion; SCC, squamous cell carcinoma; *biopsies
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the estimated technical specificity was 100% (95%CI 83.89%
to 100%).
Idylla™ agreed with standard testing in all 34 PCR
reference-tested cases (14 of 23 therascreen cases mutant, two
of 11 cobas cases mutant), giving 100% concordance (95% CI
89.85% to 100%) with routine (cobas/therascreen) PCR.
The NGS (AmpliSeq) cohort was only six cases (four mutant
cases, twowild-type cases),making a subgroup statistical analysis
of these of limited value, however, of note was there were three
discordant cases. The concordance of Idylla with NGS therefore
was only 50%. The three samples were small lung biopsies from
lung adenocarcinoma, all of which were called mutant by NGS
(see Table 2). The codon changes detected by NGS but designat-
ed wild type by Idylla™ in the three cases were exon 20 T790M
(low level 4%), exon 20 S768I and exon 21 L861Q (low level
2%). One of the three cases (same case as T790Mmutation) also
had an incidental exon 18 E709_T710delinsD detected by NGS.
This mutation is not covered by the Idylla panel and was consid-
ered to be of no clinical importance.
Discussion
EGFR testing is now an integral part of respiratory pathology
practice [21] and the clinical demand for urgent (i.e. fast) testing
in these patients with a shortmedian survival time is understand-
ably high [22]. The approach to molecular diagnostics for lung
cancer differs from centre to centre. In addition to EGFR, ALK-
rearrangement testing is also routine and there are a number of
targeted therapies for tumours harbouring the EML4-ALK fu-
sion gene [23]. PD-1/PD-L1 and ROS1 are now also becoming
routine [24, 25]. Some centres perform both EGFR and ALK
testing and some centres are using the more widely available
KRAS testing options to compliment screening (KRAS muta-
tions are generally mutually exclusive with EGFR and ALK
mutations, reducing the number of EGFR/ALK tests needed).
Many laboratories find this easier as lung cancer cases can be
batched with other (e.g. colorectal cancer) cases undergoing
KRAS testing, rather than waiting for sufficient EGFR or ALK
testing samples. Practice is variable, however, and guidelines
are not yet fully established for KRAS testing [21]. For centres,
using the RAS testing approach, the Idylla™ KRAS Mutation
Test could be integrated into this protocol—although accuracy
data for the test in this tissue needs to be generated. ALK, PD-1/
PD-L1 and ROS1 testing are not yet available on the Idylla™
platform, however more traditional approaches (immunohisto-
chemistry and/or fluorescence in situ hybridization techniques)
already work well [21, 24, 25].
In this study, we evaluated the Idylla™ platform for EGFR
testing in a representative range of lung cancer histopathology
FFPE specimens. This is the first such study to do this for the
now commercially availableCE-IVD approved for clinical use
Idylla™ EGFR Mutation Test. The results demonstrate high
agreement (92.5%) with commonly used molecular tests, al-
though there were three discordant test results. The Idylla™
also showed high estimated specificity (100%) for EGFRmu-
tation detection, although this finding is limited by a small
sample size and non-random case selection.
There were three discordant cases in this study and this
affected the concordance and overall sensitivity of the test.
All three cases had EGFR mutations that are covered by the
Idylla panel. These results were at odds with those reported by
others for EGFR and Idylla in general and were initially sur-
prising [16, 18]. These results can be explained methodolog-
ically. The comparisons were performed on small biopsies
with very limited tissue remaining in the block at the time of
Idylla™ testing. A pre-Idylla testing H&Ewas not prepared in
order to preserve tissue for the assay, but the original H&E
section before NGS testing showed greater than 40% tumour
nuclei in all three cases. A follow-up H&E section was cut and
stained for the three discordant cases after Idylla testing and
these showed that in all three blocks, there were no tumour
cells remaining. It is likely that in these cases, there was no
tumour DNA present in the samples assayed and that these
results do not reflect true discordance. The data could have been
improved with a greater number of NGS cases for comparison,
but unfortunately, in this small evaluation, there was no funding
to cover this. The power of the results could be improved by
excluding NGS cases from the statistical analysis altogether;
however, it was preferred by the authors to openly publish all
data—the inference of the exclusion can still be drawn in the
subgroup analysis of the results for PCR alone. This does show
the high concordance of Idylla™ with routine PCR.
Although the discordant results were likely due to method-
ological limitations, some evaluation of the clinical relevance
of these (if true discordances) can be speculated. The exon 21
mutation was present at a level of only 2% in the NGS assay
and the exon 20 T790M mutation was only detected at 4%;
therefore, it is unlikely that cobas or therascreen PCR (the
more commonly used assays) would have detected these ei-
ther. Clinical trial data are limited on the response to initial
therapy in patients with these three mutations and so it is not
clear if the discordance with Idylla™ is clinically important in
these samples anyway [9, 26–30]. Furthermore, T790 is gen-
erally more important as a resistance mutation, following
EGFR-TKi therapy [31].
Table 3 A summary of the results from the comparison of Idylla against
reference testing for EGFR mutations
Reference test mutant Reference test WT Total
Idylla positive 17 0 17
Idylla negative (WT) 3 20 23
Total 20 20 40
WT, wild type
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The Idylla™ EGFR Mutation Test compared with cobas
and therascreen PCR assays alone (34 cases) showed 100%
concordance. Thus, if NGS cases were excluded from the
analysis, this gives an estimated technical sensitivity and spec-
ificity of 100%. The main aim of this study was to compare
the Idylla with routine PCR because this is probably still the
most widely used methodology in Europe (NGS panels are
rarely CE approved). The results demonstrate that Idylla is at
least as good as the standard care CE–marked testing that is in
common use. In light of the fact that the majority of centres are
probably still using PCR-based tests, it can be said that the
Idylla™ EGFR Mutation Test performs equally well as stan-
dard care tests for the majority of common and well-
characterised lung cancer EGFR mutations. The system also
offers significant advantages in terms of turn-around times.
With the future shift to NGS being extremely likely, some
centres may opt for a rapid PCR-based EGFR screening test
initially in urgent cases and follow this up with NGS later. In
this scenario, the Idylla™ would be best suited.
NICE primarily recommends using FFPE tumour biopsy
tissue for EGFR testing, but acknowledges that often these sam-
ples are very small and that testing cytological material may be
useful where no tissue is available after the histological assess-
ment has been carried out [5]. A larger study that includes
cytological and fresh tissue sampleswith Idylla™may therefore
be warranted. NICE does not specifically comment on the fi-
nancial implications of different testingmodalities. The Idylla™
EGFR Mutation Test costs around £170 per test (Europe-wide
average, depending on pricing structure) and is therefore com-
parable with most conventional EGFR PCR assays. In compar-
ison, the cost of NGS gene panels is currently around £300.
Therefore, depending on the local arrangements, Idylla™ could
potentially reduce costs for some institutions, but for others, this
might not be cost effective and the additional financial commit-
ment would need to be balanced against the clinical benefits of
reduced turn-around time (which may also be cost saving). A
full health economics evaluation of molecular testing in lung
cancer could be very helpful.
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